1-8 of 8
Fiona Taylor
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-Related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Final Data from the Phase 2 ELOQUENT-3 Trial

Katja Weisel, Meletios A. Dimopoulos, Jesús San-Miguel, Agne Paner, Monika Engelhardt, Fiona Taylor, Jennifer Lord-Bessen, David Yao, Christine Yip, Mike Greenwood, Jackson Tang, Michele Cavo
Journal: Blood
Blood (2021) 138 (Supplement 1): 1662.
https://doi.org/10.1182/blood-2021-145310
Published: 2021
Journal Articles

Health-Related Quality-of-Life Outcomes in Patients with Classical Hodgkin Lymphoma: A Prospective, Observational Study in US Oncology Practices

Jakub Svoboda, MD, Philippe Armand, MD PhD, Fiona Taylor, Xiaowu Sun, Alejandro Moreno-Koehler, Srikanth Gajavelli, MD, Derek Peterson, Clara Chen, PhD BS, MS
Journal: Blood
Blood (2019) 134 (Supplement_1): 2192.
https://doi.org/10.1182/blood-2019-123980
Published: 2019
Journal Articles

Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study

Katja Weisel, Agne Paner, MD, Monika Engelhardt, MD, Fiona Taylor, Kim Cocks, Mihaela Popa-McKiver, PhD, Clara Chen, PhD BS, MS, Michele Cavo
Journal: Blood
Blood (2019) 134 (Supplement_1): 3480.
https://doi.org/10.1182/blood-2019-122232
Published: 2019
Journal Articles

Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study

Katja Weisel, MD, Agne Paner, MD, Monika Engelhardt, MD, Fiona Taylor, Kim Cocks, Ashlee Espensen, Mihaela Popa-McKiver, PhD, Clara Chen, PhD BS, MS, Michele Cavo, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2288.
https://doi.org/10.1182/blood-2018-99-112080
Published: 2018
Journal Articles

Effect of Nivolumab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma after Autologous Transplantation: Results from the Multicohort Phase 2 Checkmate 205 Study

Andreas Engert, MD, Fiona Taylor, Bryan Bennett, Clara Chen, PhD BS, MS, Kim Cocks, Jeffrey McDonald, Erin Mann, Mariana Sacchi, David Cella, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3441.
https://doi.org/10.1182/blood.V130.Suppl_1.3441.3441
Published: 2017
Journal Articles

Patient Subgroup Analysis of Quality-of-Life Outcomes in Checkmate 205, a Phase 2 Study of Nivolumab in Patients with Classical Hodgkin Lymphoma

Andreas Engert, MD, Fiona Taylor, Bryan Bennett, Ishan Hirji, Kim Cocks, Jeffrey McDonald, Erin Mann, Kazunobu Kato, MD, David Cella, PhD
Journal: Blood
Blood (2016) 128 (22): 1831.
https://doi.org/10.1182/blood.V128.22.1831.1831
Published: 2016
Journal Articles

Qualitative Assessment Of Symptoms and Functional Impact In Relapsed/Refractory Multiple Myeloma Patients and Comparison To The EORTC QLQ-C30 and My-20, FACT-MM, and MDASI-MM

Peter C Trask, PhD, MPH, Fiona Taylor, MBiochem, Alan Shields, PhD, Meghan Gallagher, MSc, Jyotsna Mehta, MSc, Catherine Foley, MPH, Funke Olude, MPH, Roger Lamoureux, Ramon Iovin, PhD, Karl Hsu, MD
Journal: Blood
Blood (2013) 122 (21): 2989.
https://doi.org/10.1182/blood.V122.21.2989.2989
Published: 2013
Journal Articles

Quality of Life and Productivity Impact of Myelodysplastic Syndromes (MDS): The Patient Perspective

Dalia Mahmoud, MBA, Stacie Hudgens, MS, Fiona Taylor, MBiochem, Farrah Pompilus, MA, Steve Hwang, BA, C.L. Beach, PharmD
Journal: Blood
Blood (2012) 120 (21): 4705.
https://doi.org/10.1182/blood.V120.21.4705.4705
Published: 2012